المؤلفون: Brufsky, Adam, Liu, Xianchen, Li, Benjamin, McRoy, Lynn, Chen, Connie, Layman, Rachel M., Rugo, Hope S.

المصدر: Cancers; Nov2023, Vol. 15 Issue 21, p5268, 15p

مصطلحات موضوعية: THERAPEUTIC use of antineoplastic agents, PROFESSIONAL practice, LIVER tumors, ENDOCRINE diseases, HORMONE therapy, LUNG tumors, METASTASIS, RETROSPECTIVE studies, ACQUISITION of data, CYCLIN-dependent kinases, CANCER patients, TREATMENT effectiveness, AROMATASE inhibitors, MEDICAL records, RESEARCH funding, PROGRESSION-free survival, BREAST tumors, OVERALL survival

مصطلحات جغرافية: UNITED States

مستخلص: Simple Summary: Palbociclib combined with an aromatase inhibitor (AI) has been shown to be effective in clinical trials for people with HR+/HER2− breast cancer that has spread to other areas of the body, such as the lungs or liver. Evidence of palbociclib effectiveness in routine clinical practice can provide complementary support for clinical trial findings. This study used electronic health records of people with breast cancer that had spread to their lungs and/or liver to determine how well palbociclib plus an AI worked compared to an AI alone. The study showed that palbociclib plus an AI compared with an AI alone was associated with a 38% or 27% reduction in the risk of death for patients with breast cancer that had spread to the lungs or liver, respectively. These findings support the use of palbociclib plus an AI for people whose breast cancer has spread to their lungs or liver. A cyclin-dependent kinase 4/6 inhibitor combined with endocrine therapy is the standard of care for patients with hormone receptor-positive/human epidermal growth factor 2-negative (HR+/HER2−) metastatic breast cancer (mBC), but real-world effectiveness data for patients with lung or liver metastases are limited. This retrospective study included data from the US Flatiron Health database of patients with HR+/HER2− mBC and lung or liver metastases treated with first-line palbociclib (PAL) plus an aromatase inhibitor (AI) or an AI alone in routine clinical practice. Overall survival (OS) and real-world progression-free survival (rwPFS) were assessed. A total of 891 patients were included (622 with lung metastasis, 376 with liver metastasis, and 107 with both lung and liver metastasis). After stabilized inverse probability of treatment weighting to balance patient characteristics, PAL + AI versus AI alone was associated with significantly prolonged OS (HR = 0.62; p < 0.001) and rwPFS (HR = 0.55; p < 0.001) in patients with lung metastases and numerically longer OS (HR = 0.73; p = 0.056) and significantly longer rwPFS (HR = 0.57, p < 0.001) for those with liver metastases. Overall, PAL + AI versus AI alone was associated with prolonged OS and rwPFS in routine clinical practice, supporting the use of first-line PAL + AI for patients with HR+/HER2− mBC with lung and/or liver metastases. [ABSTRACT FROM AUTHOR]

: Copyright of Cancers is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

المؤلفون: Elghazaly, Hesham¹ (AUTHOR) Heshamelghazaly@med.asu.edu.eg, Rugo, Hope S.² (AUTHOR) Heshamelghazaly@med.asu.edu.eg, Azim, Hamdy A.³ (AUTHOR) azimonc@cairocure.com, Swain, Sandra M.⁴ (AUTHOR) sms248@georgetown.edu, Arun, Banu⁵ (AUTHOR) barun@mdanderson.org, Aapro, Matti⁶ (AUTHOR) maapro@genolier.net, Perez, Edith A.⁷ (AUTHOR) perez.edith@mayo.edu, Anderson, Benjamin O.⁸ (AUTHOR) banderso@fredhutch.org, Penault-Llorca, Frederique⁹ (AUTHOR) Frederique.PENAULT-LLORCA@clermont.unicancer.fr, Conte, Pierfranco¹⁰ (AUTHOR) pierfranco.conte@unipd.it, El Saghir, Nagi S.¹¹ (AUTHOR) ns23@aub.edu.lb, Yip, Cheng-Har¹² (AUTHOR) chenghar.yip@gmail.com, Ghosn, Marwan¹³ (AUTHOR) marwanghosnmd@yahoo.com, Poortmans, Philip¹⁴ (AUTHOR) philip.poortmans@telenet.be, Shehata, Mohamed A.¹⁵ (AUTHOR) Mohamed.Shehata@med.menofia.edu.eg, Giuliano, Armando E.¹⁶ (AUTHOR) armando.giuliano@cshs.org, Leung, Jessica W. T.¹⁷ (AUTHOR) jwleung@mdanderson.org, Guarneri, Valentina¹⁰ (AUTHOR) valentina.guarneri@unipd.it, Gligorov, Joseph¹⁸ (AUTHOR) joseph.gligorov@aphp.fr, Gulluoglu, Bahadir M.¹⁹ (AUTHOR) bmgulluoglu@marmara.edu.tr

المصدر: Cancers. May2021, Vol. 13 Issue 9, p2262-2262. 1p.

مصطلحات موضوعية: *BREAST tumor treatment, *CONSENSUS (Social sciences), *GENETIC mutation, *BRCA genes, *CONFERENCES & conventions, *VOTING, *MEDICAL protocols, *DISEASE management, *IMMUNOTHERAPY

الشركة/الكيان: AMERICAN Society of Clinical Oncology 148674880

مستخلص: Simple Summary: Despite the impressive progress in the treatment of triple-negative breast cancer (TNBC), oncologists still face several provocative clinical scenarios in daily practice where clear evidence-based recommendations are lacking, and expert opinion is of utmost importance. In an attempt to seek guidance for these controversial topics in TNBC management, a consensus recommendations session for TNBC was held during the 12th round of the Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020. This special session convened a multidisciplinary committee of 35 panellists who specialize in breast cancer care from 13 countries. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials. Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials. [ABSTRACT FROM AUTHOR]

المؤلفون: Jessica W.T. Leung, Sana Al-Sukhun, Omalkhair Abulkhair, Benjamin O. Anderson, Meteb Foheidi, Nagi S. El Saghir, Hany Abdel Aziz, Joseph Gligorov, Mohamed Sabry, Hamdy A. Azim, Hagar Elghazawy, Edith A. Perez, Frédérique Penault-Llorca, Bahadir M. Gulluoglu, Joaira Bakkach, Khaled Abdel Karim, Banu Arun, Pierfranco Conte, Valentina Guarneri, Hope S. Rugo, Hesham Elghazaly, Mohamed A Shehata, Mona Frolova, Philip Poortmans, Cheng Har Yip, Sandra M. Swain, Manal Mohamed El-mahdy, Nermean Bahie Eldin, Alaa Kandil, Mohamed El-Shinawi, Charles M. Balch, Marwan Ghosn, Wentao Yang, Matti Aapro, Heba M. El-Zawahry, Adel T. Aref, Armando E. Giuliano, Roberto Orecchia, Ruslan M. Paltuev

المساهمون: Ain Shams University (ASU), Department of Medicine, University of California San Francisco Comprehensive Cancer Center, San Francisco, CA 94158, Clinical Oncology Department, Kasr Alainy School of Medicine, Cairo University, Giza 12613, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, MedStar Health, Washington, DC 20007, Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, Breast Center, Clinique de Genolier, 1272 Genolier, Department of Hematology & Oncology, Mayo Clinic, Jacksonville, FL 32224, University of Washington [Seattle], Imagerie Moléculaire et Stratégies Théranostiques (IMoST), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Clermont Auvergne (UCA), Centre Jean Perrin [Clermont-Ferrand] (UNICANCER/CJP), UNICANCER, Department of Surgery, Oncology and Gastroenterology, University of Padova, Istituto Oncologico Veneto IOV IRCCS, 35128 Padova, Department of Internal Medicine, Division of Hematology Oncology, American University of Beirut Medical Center, Beirut 1107 2020, Subang Jaya Medical Centre, Kuala Lumpur 47500, Université Saint-Joseph de Beyrouth (USJ), University of Antwerp (UA), Clinical oncology Department, Menoufia University, Shebin Elkom 51132, Department of Surgery, Surgical Oncology Division, Cedars-Sinai Medical Center, Los Angeles, CA 90048, Department of Breast Imaging, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Breast & Endocrine Surgery Unit, Marmara University School of Medicine, University Hospital, Istanbul 34722, Federal State Budgetary Institution 'NN Blokhin National Medical Research Center of Oncology' of the Ministry of Health of the Russian Federation, 127994 Moscow, Surgical Oncology Department, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, Università degli Studi di Milano = University of Milan (UNIMI), Al Hyatt Oncology Practice, Amman 11183, Department of Clinical Oncology, Alexandria School of Medicine, Alexandria 21131, Russian Association of Oncological Mammology, Department of Breast Tumours of Federal State Budgetary Institution 'Petrov Research Institute of Oncology', 197758 Saint Petersburg, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Adult Medical Oncology, Princess Noorah Oncology Center, King Abdulaziz Medical City, Ministry of National Guard Health Affairs-Western Region, Jeddah 22384, Vice President of Galala University, Galala University, Suez 435611, Oncology Department, Alfaisal university, Alhabib Hospital, Riyad 11533, Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, University of Adelaide, Biomedical Genomics & Oncogenetics Research Laboratory, Faculty of Sciences and Techniques of Tangier, Abdel Malek Essaadi University, Tangier 90000, Elghazaly, Hesham, Rugo, Hope S., Azim, Hamdy A., Swain, Sandra M., Arun, Banu, Aapro, Matti, Perez, Edith A., Anderson, Benjamin O., Penault-Llorca, Frederique, Conte, Pierfranco, El Saghir, Nagi S., Yip, Cheng-Har, Ghosn, Marwan, Poortmans, Philip, Shehata, Mohamed A., Giuliano, Armando E., Leung, Jessica W. T., Guarneri, Valentina, Gligorov, Joseph, Gulluoglu, Bahadir M., Abdel Aziz, Hany, Frolova, Mona, Sabry, Mohamed, Balch, Charles M., Orecchia, Roberto, El-Zawahry, Heba M., Al-Sukhun, Sana, Abdel Karim, Khaled, Kandil, Alaa, Paltuev, Ruslan M., Foheidi, Meteb, El-Shinawi, Mohamed, ElMahdy, Manal, Abulkhair, Omalkhair, Yang, Wentao, Aref, Adel T., Bakkach, Joaira, Bahie Eldin, Nermean, Elghazawy, Hagar, Clinical Oncology Department, Faculty of Medicine, Ain Shams University, Cairo 11566, Breast Health Global Initiative, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA 98195, Hematology and Oncology Department, Saint Joseph University, Beirut 1104 2020, Iridium Kankernetwerk and Faculty of Medicine and Health Sciences, University of Antwerp, 2610 Wilrijk-Antwer, Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Scientific Directorate, IRCCS European Institute of Oncology (IEO), and University of Milan, 20122 Milan, Department of General Surgery, Faculty of Medicine, Ain Shams University, Cairo 11566, Department of Pathology, Ain shams University, Cairo 11566, The School of Public Health, University of Adelaide, Adelaide 5005

المصدر: Cancers, Vol 13, Iss 2262, p 2262 (2021)
Cancers
Cancers, 2021, 13 (9), pp.2262. ⟨10.3390/cancers13092262⟩
Cancers, MDPI, 2021, 13 (9), pp.2262. ⟨10.3390/cancers13092262⟩

مصطلحات موضوعية: 0301 basic medicine, Cancer Research, medicine.medical_specialty, POSTMASTECTOMY RADIOTHERAPY, medicine.medical_treatment, [SDV]Life Sciences [q-bio], education, COMPLETE RESPONSE PCR, Disease, MUTATION CARRIERS, Guidelines, 03 medical and health sciences, NEOADJUVANT CHEMOTHERAPY, 0302 clinical medicine, Breast cancer, ADJUVANT CHEMOTHERAPY, medicine, DISEASE-FREE SURVIVAL, TUMOR-INFILTRATING LYMPHOCYTES, platinum, LOCOREGIONAL RECURRENCE, AMERICAN SOCIETY, Triple-negative breast cancer, RC254-282, business.industry, BRCA mutations, Consensus, Immunotherapy, Platinum, Cancer conference, Consensus conference, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Evidence-based medicine, RANDOMIZED PHASE-III, medicine.disease, 3. Good health, Clinical trial, 030104 developmental biology, Oncology, consensus, 030220 oncology & carcinogenesis, Family medicine, triple-negative breast cancer, Human medicine, immunotherapy, business, Mastectomy

الوصف: Simple Summary Despite the impressive progress in the treatment of triple-negative breast cancer (TNBC), oncologists still face several provocative clinical scenarios in daily practice where clear evidence-based recommendations are lacking, and expert opinion is of utmost importance. In an attempt to seek guidance for these controversial topics in TNBC management, a consensus recommendations session for TNBC was held during the 12th round of the Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020. This special session convened a multidisciplinary committee of 35 panellists who specialize in breast cancer care from 13 countries. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials. Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when >= 75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.

وصف الملف: application/pdf

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa1c2dcd7aefedfe4cf1b8a949aff343Test
https://www.mdpi.com/2072-6694/13/9/2262Test